Clinical trials: Squamous Cell Carcinoma of the Oral Cavity
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT05136196
- Testing
- Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate
- Where
- 231 sites in United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 201 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other…
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- NCT00588770
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 779 sites in United States, Puerto Rico and 1 more
- Volunteers
- 403 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell…
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04671667
- Testing
- Carboplatin, Cisplatin, Computed Tomography
- Where
- 178 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Lip, Oral Cavity Squamous Cell Carcinoma
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck.
- Conditions
- Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx
- Trial name
- NCT03854032
- Testing
- Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Thomas Jefferson University
HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during…
- Conditions
- HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery
- Trial name
- NCT07741643
- Testing
- Panitumumab-IRDye800, [18F]NOTA-ABY-030
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma
Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy
Non-commercial clinical study to assess: 1. efficacy of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma. 2.
- Conditions
- Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma, Larynx Carcinoma, Paranasal Sinus Carcinoma
- Trial name
- iCHRTL (NCT05992610)
- Testing
- Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma
- Trial name
- NCT06980038
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Hnscc, Head and Neck
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this Phase 1 clinical trial is to evaluate the safety and feasibility of nivolumab-IRDye800CW (nivo800) as a molecular imaging agent in adults with biopsy-confirmed or presumed head and neck squamous cell carcinoma…
- Conditions
- Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma
- Trial name
- NCT07460765
- Testing
- Nivo800, Nivolumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer…
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT01810913
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 342 sites in United States, Canada and 1 more
- Volunteers
- 613 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy…
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07195734
- Testing
- Biospecimen Collection, Carboplatin, Cemiplimab
- Where
- 113 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
This phase I trial investigates the side effects and best dose of peposertib when given together with radiation therapy in treating patients with head and neck cancer that has spread to other places in the body (advanced) who…
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04533750
- Testing
- Intensity-Modulated Radiation Therapy, Peposertib
- Where
- 27 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
HNSCC, Lip SCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC.
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT03082534
- Testing
- Pembrolizumab, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Diego
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05063552
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 172 sites in United States
- Volunteers
- 430 people
- Sponsor
- National Cancer Institute (NCI)
Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for…
- Trial name
- NCT07844551
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab, Cisplatin
- Volunteers
- 40 people
- Sponsor
- Huashan Hospital
Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders
Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage
This research study evaluates an experimental, point-of-care tool that combines Deep Ultraviolet (DUV) light imaging with Artificial Intelligence (AI) to rapidly screen for oral cancer and pre-cancer (dysplasia).
- Conditions
- Oral Potentially Malignant Lesions, Oral Potentially Malignant Disorders, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Oral Cancer
- Trial name
- DEEP UV-M (NCT07842211)
- Testing
- Deep UV-M and AI Cytology Triage
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Anh Le
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer.
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05172245
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- 18 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the head and neck that has come back (recurrent) or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT05172258
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 20 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients.
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC
- Trial name
- NCT06736379
- Testing
- VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- VLP Therapeutics
Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery.
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8
- Trial name
- NCT05316688
- Testing
- Near Infrared Imaging, Therapeutic Conventional Surgery, Tozuleristide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington